CL2011001221A1 -
Therapeutic composition comprising an anti-interleukin-6 antibody (ab1); use of an ab1 antibody to treat, prevent or diagnose a disease or condition associated with il-6
- Google Patents
Therapeutic composition comprising an anti-interleukin-6 antibody (ab1); use of an ab1 antibody to treat, prevent or diagnose a disease or condition associated with il-6
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filedlitigationCriticalhttps://patents.darts-ip.com/?family=66221432&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CL2011001221(A1)"Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from US12/366,567external-prioritypatent/US8062864B2/en
Priority claimed from US12/391,717external-prioritypatent/US8178101B2/en
Application filed by Alder Biopharmaceuticals IncfiledCriticalAlder Biopharmaceuticals Inc
Publication of CL2011001221A1publicationCriticalpatent/CL2011001221A1/en
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents
(AREA)
Abstract
Composición terapéutica que comprende un anticuerpo anti-interleuquina-6 (ABI); uso de un anticuerpo ABI para tratar, prevenir o diagnosticar una enfermedad o afección asociada con la il-6.Therapeutic composition comprising an anti-interleukin-6 antibody (ABI); use of an ABI antibody to treat, prevent or diagnose a disease or condition associated with il-6.
CL2011001221A2008-11-252011-05-25
Therapeutic composition comprising an anti-interleukin-6 antibody (ab1); use of an ab1 antibody to treat, prevent or diagnose a disease or condition associated with il-6
CL2011001221A1
(en)
Therapeutic composition comprising an anti-interleukin-6 antibody (ab1); use of an ab1 antibody to treat, prevent or diagnose a disease or condition associated with il-6
Use of compound genz-112638 (eliglustat), glucosylceramide synthase inhibitor, in the treatment of gaucher disease and fabry disease (divisional application 201201348).
Antibody or antibody fragment against humanized antibody cd38, conjugated to the antibody with a cytotoxic compound pharmaceutical composition with said antibodies using antibodies to treat cancer or autoimmune disease method to diagnose cancer polynucleotide vector and host cell.
Compounds derived from prostaglandin e2 inhibitor 2-arylamino-benzimidazoles (mpges-1); pharmaceutical composition that includes them; intermediary compounds; use in the treatment of inflammatory diseases and / or associated conditions, in particular pain.
Antibody or fragment thereof with neutralizing activity of protein nr 10; agent who understands it; and its use to prevent or treat an inflammatory disease.
COMBINED THERAPY FOR THE TREATMENT OF DIABETES AND RELATED AFFECTIONS AND FOR THE TREATMENT OF AFFECTIONS THAT IMPROVE THROUGH AN INCREASE IN THE SANGUINEA CONCENTRATION OF GLP-1
Compounds derived from 5-phenyl-1h-pyridin-2-one and 6-phenyl-2h-pyridazin-3-one, tyrosine kinase inhibitors (btk); Pharmaceutical composition comprising said compounds and their use for the treatment of an inflammatory and / or autoimmune pathological state.
Substituted 2-amino-acetamide derived compounds; pharmaceutical composition; Useful in the treatment of lung diseases, rheumatic disease, autoimmune disease, among others.